Analyzing Park-Ohio (NASDAQ:PKOH) and Cyclacel Pharmaceuticals (NASDAQ:BGMS)

Cyclacel Pharmaceuticals (NASDAQ:BGMS) and Park-Ohio (NASDAQ:PKOH) are both small-cap industrials companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, dividends, profitability, earnings, risk and valuation.

Profitability

This table compares Cyclacel Pharmaceuticals and Park-Ohio’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Cyclacel Pharmaceuticals	-118.27%	-31.60%	-27.72%
Park-Ohio	1.60%	10.55%	2.81%

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Cyclacel Pharmaceuticals and Park-Ohio, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cyclacel Pharmaceuticals	1	0	0	0	1.00
Park-Ohio	0	2	1	0	2.33

Park-Ohio has a consensus price target of $59.00, suggesting a potential upside of 24.16%. Given Park-Ohio’s stronger consensus rating and higher possible upside, analysts plainly believe Park-Ohio is more favorable than Cyclacel Pharmaceuticals.

Institutional & Insider Ownership

23.6% of Cyclacel Pharmaceuticals shares are held by institutional investors. Comparatively, 51.4% of Park-Ohio shares are held by institutional investors. 23.7% of Cyclacel Pharmaceuticals shares are held by insiders. Comparatively, 31.1% of Park-Ohio shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Earnings and Valuation

This table compares Cyclacel Pharmaceuticals and Park-Ohio”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cyclacel Pharmaceuticals	$1.86 million	2.87	-$3.00 million	($3.64)	-0.27
Park-Ohio	$1.65 billion	0.42	$23.80 million	$1.88	25.28

Park-Ohio has higher revenue and earnings than Cyclacel Pharmaceuticals. Cyclacel Pharmaceuticals is trading at a lower price-to-earnings ratio than Park-Ohio, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Cyclacel Pharmaceuticals has a beta of -0.4, meaning that its share price is 140% less volatile than the S&P 500. Comparatively, Park-Ohio has a beta of 1.22, meaning that its share price is 22% more volatile than the S&P 500.

Summary

Park-Ohio beats Cyclacel Pharmaceuticals on 13 of the 14 factors compared between the two stocks.

About Cyclacel Pharmaceuticals

Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company’s development programs include fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and CYC140, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced leukemias and solid tumors. Its development programs also comprise Sapacitabine, a novel nucleoside analog that is orally available prodrug of CNDAC, which is in Phase 1/2 clinical trials to treat acute myeloid leukemia and myelodysplastic syndrome; and seliciclib, a CDK inhibitor that is in Phase 2 investigator-sponsored trials (IST) for Cushing’s disease, as well as in Phase 1/2 IST for the treatment for advanced rheumatoid arthritis. The company has a clinical collaboration agreement with the University of Texas MD Anderson Cancer Center to clinically evaluate the safety and efficacy of three cyclacel medicines in patients with hematological malignancies, including chronic lymphocytic leukemias, acute myeloid leukemias, myelodysplastic syndromes, and other advanced leukemias. Cyclacel Pharmaceuticals, Inc. is headquartered in Berkeley Heights, New Jersey.

About Park-Ohio

Park-Ohio Holdings Corp. provides supply chain management outsourcing services, capital equipment, and manufactured components in the United States, Europe, Asia, Mexico, Canada, and internationally. It operates through three segments: Supply Technologies, Assembly Components, and Engineered Products. The Supply Technologies segment offers Total Supply Management that comprises engineering and design support, part usage and cost analysis, supplier selection, quality assurance, bar coding, product packaging and tracking, just-in-time and point-of-use delivery, electronic billing, and ongoing technical support services, as well as provides spare parts and aftermarket products; and production components, such as valves, fuel hose assemblies, electro-mechanical hardware, labels, fittings, steering components, and other products. This segment also engineers and manufactures precision cold-formed and cold-extruded fasteners, and other products comprising locknuts, SPAC nuts, SPAC bolts, and wheel hardware. The Assembly Components segment offers direct fuel injection fuel rails and pipes, fuel filler pipes, and flexible multi-layer plastic and rubber assemblies; turbo charging and coolant hoses; and value-added services comprising design engineering, machining, and parts assembly. The Engineered Products segment provides engineered products, including induction heating and melting systems, pipe threading systems, and forged and machined products for ferrous and non-ferrous metals, silicon, coatings, forging, foundry, automotive, and construction equipment industries; engineers and installs mechanical forging presses; sells spare parts; field services; and forges aerospace and defense structural components, such as landing gears and struts, as well as rail products comprising railcar center plates and draft lugs. Park-Ohio Holdings Corp. was founded in 1907 and is headquartered in Cleveland, Ohio.